Ignite Creation Date:
2025-12-24 @ 5:08 PM
Ignite Modification Date:
2025-12-28 @ 8:43 PM
Study NCT ID:
NCT04865250
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2021-03-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
Sponsor:
University Hospital Heidelberg
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-01-07
Start Date Type:
ACTUAL
Primary Completion Date:
2024-11-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2021-03-08
First Submit QC Date:
None
Study First Post Date:
2021-04-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-13
Last Update Post Date:
2024-05-16
Last Update Post Date Type:
ACTUAL